AB Science S.A Market Cap ($61.84 Million)
Market Cap & Net Worth: AB Science S.A (AB)
AB Science S.A market cap. AB Science S.A (PA:AB) has a market capitalization of $61.84 Million (€52.90 Million) as of October 31, 2026. Listed on the PA stock exchange, this France-based company holds position #20954 globally and #325 in its home market, demonstrating a -3.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AB Science S.A's stock price €0.55 by its total outstanding shares 96530783 (96.53 Million).
AB Science S.A Market Cap History (2015–2026)
AB Science S.A market cap history from 2015 to 2026. Data shows change from $1.38 Billion to $61.84 Million (-24.47% CAGR). Check AB live share price for real-time trading data and today's change.
AB Science S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AB Science S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see AB Science S.A operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
147.65x
AB Science S.A's market cap is 147.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.54 Billion | $1.51 Million | -$27.70 Million | 1023.77x | N/A |
| 2017 | $941.21 Million | $1.74 Million | -$27.12 Million | 541.23x | N/A |
| 2018 | $391.38 Million | $1.70 Million | -$26.06 Million | 230.09x | N/A |
| 2019 | $607.16 Million | $1.57 Million | -$21.75 Million | 386.48x | N/A |
| 2020 | $2.22 Billion | $1.58 Million | -$15.04 Million | 1401.59x | N/A |
| 2021 | $1.35 Billion | $1.61 Million | -$14.46 Million | 842.72x | N/A |
| 2022 | $800.14 Million | $958.00K | -$13.62 Million | 835.22x | N/A |
| 2023 | $401.20 Million | $970.00K | -$10.05 Million | 413.61x | N/A |
| 2024 | $99.54 Million | $1.07 Million | -$7.83 Million | 92.85x | N/A |
| 2025 | $173.34 Million | $1.17 Million | -$1.56 Million | 147.65x | N/A |
Competitor Companies of AB by Market Capitalization
Companies near AB Science S.A in the global market cap rankings as of October 31, 2026. See AB equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to AB Science S.A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of AB Science S.A (2015–2026)
Market capitalization of AB Science S.A from 2015 to today. Between 2015 and today, AB Science S.A's market cap moved from $1.38 Billion to $ 61.84 Million, with a yearly change of -24.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €61.84 Million | -64.32% |
| 2025 | €173.34 Million | +74.15% |
| 2024 | €99.54 Million | -75.19% |
| 2023 | €401.20 Million | -49.86% |
| 2022 | €800.14 Million | -40.92% |
| 2021 | €1.35 Billion | -38.96% |
| 2020 | €2.22 Billion | +265.43% |
| 2019 | €607.16 Million | +55.13% |
| 2018 | €391.38 Million | -58.42% |
| 2017 | €941.21 Million | -39.04% |
| 2016 | €1.54 Billion | +11.86% |
| 2015 | €1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of AB Science S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.84 Million USD |
| MoneyControl | $61.84 Million USD |
| MarketWatch | $61.84 Million USD |
| marketcap.company | $61.84 Million USD |
| Reuters | $61.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more